As­traZeneca’s on­col­o­gy R&D chief Su­san Gal­braith high­lights their next-gen prospects at #AACR22

4 years ago
R&D

Qui­et CD­MO makes noise, throw­ing down $500M for man­u­fac­tur­ing cam­pus and mov­ing for­ward with Chi­na op­er­a­tions

4 years ago
Pharma
Manufacturing

In­side the UK's push to ad­dress the an­timi­cro­bial cri­sis with a Net­flix-style sub­scrip­tion mod­el

4 years ago
Pharma

How a phar­ma com­pa­ny bought 2 ac­cel­er­at­ed ap­provals — nev­er ran con­fir­ma­to­ry tri­als — and cashed in un­til FDA ...

4 years ago
Pharma
FDA+

Drug pro­mo po­lice slap Bausch Health with un­ti­tled let­ter over pso­ri­a­sis drug TV and dig­i­tal mar­ket­ing

4 years ago
Pharma
FDA+

Abzena com­mits chunk of new $65M in­vest­ment to build out in hot North Car­oli­na scene

4 years ago
Pharma
Manufacturing

What hap­pened to all the 'good' drug names? In­side the mod­ern day dilem­ma of Rx nam­ing

4 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Coun­try mu­sic awards and more phar­ma ads; Bris­tol My­ers ad­vances clin­i­cal tri­al di­ver­si­ty ef­fort

4 years ago
Pharma
Marketing

Au­ri­on rais­es $120M in bid to scale cell ther­a­py for form of blind­ness

4 years ago
Startups

Five Prime tri­al in­ves­ti­ga­tor pleads guilty to $134K in­sid­er trad­ing scheme, faces up to 25 years in prison

4 years ago
Law

Stan­ford spin­out racks up more sup­port for its mR­NA ap­proach to cel­lu­lar re­ju­ve­na­tion

4 years ago
Financing
Startups

Backed by bil­lion­aire Mike Platt, En­gi­tix scores an­oth­er deal with Take­da to go af­ter IBD

4 years ago
Startups
Deals

Man­u­fac­tur­ing prob­lems trig­ger an­oth­er clin­i­cal hold for trou­bled Covid-19 vac­cine — lat­est in a string of ...

4 years ago
Coronavirus
Manufacturing

My­ovant and Pfiz­er’s path to se­cur­ing a sec­ond nod for Myfem­bree gets hazy — and in­vestors re­act quick­ly  

4 years ago
R&D
FDA+

Thou­sands of lay­offs planned as part of No­var­tis re­struc­tur­ing — re­port

4 years ago
People
Pharma

As FDA lifts clin­i­cal hold on its $4.9B CD47 drug, Gilead talks 2023 read­out, 'un­wa­ver­ing' con­fi­dence

4 years ago
FDA+

No­var­tis jumps in­to the KRAS race with a pos­i­tive ear­ly snap­shot — and a full slate of tri­als planned for am­bi­tious ...

4 years ago
R&D

FDA qui­et­ly chats with states on drug im­port plans — sig­nal­ing Biden is­n't ready to dis­pense with Trump's idea

4 years ago
Pharma
FDA+

Fed­er­al ap­peals court over­turns $137M patent ver­dict against Roche — but the case is­n't closed just yet

4 years ago
Pharma
Law

Am­gen re­ju­ve­nates En­brel ad cam­paign as biosim­i­lars re­main side­lined

4 years ago
Pharma
Marketing

Phar­ma firms make new pledge to launch in all Eu­ro mar­kets at least 2 years post-au­tho­riza­tion

4 years ago
Pharma

Bal­loon­ing 340B mar­ket reach­es al­most 15% of 2021 US phar­ma sales, IQVIA finds

4 years ago
Pharma

Texas ju­ry awards Seagen near­ly $42M in En­her­tu patent case

4 years ago
Pharma
Law

Hours af­ter Pfiz­er, Mod­er­na names its own new CFO with den­tal, health­care and au­to chops

4 years ago
People
Pharma
First page Previous page 550551552553554555556 Next page Last page
A service from the Financial Times